vs
Dorman Products, Inc.（DORM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Dorman Products, Inc.的1.4倍（$772.1M vs $537.9M），Revvity净利率更高（12.7% vs 2.1%，领先10.6%），Revvity同比增速更快（5.9% vs 0.8%），Revvity自由现金流更多（$161.8M vs $33.5M），过去两年Revvity的营收复合增速更高（9.0% vs 7.1%）
多尔曼产品公司是美国知名的汽车售后配件制造商，成立于1918年，总部位于宾夕法尼亚州科尔马，在纳斯达克上市，股票代码为DORM，深耕汽车售后市场多年，为市场提供丰富的替换零部件产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DORM vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$537.9M
营收增速更快
RVTY
高出5.1%
0.8%
净利率更高
RVTY
高出10.6%
2.1%
自由现金流更多
RVTY
多$128.3M
$33.5M
两年增速更快
RVTY
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $537.9M | $772.1M |
| 净利润 | $11.6M | $98.4M |
| 毛利率 | 42.6% | — |
| 营业利润率 | 5.8% | 14.5% |
| 净利率 | 2.1% | 12.7% |
| 营收同比 | 0.8% | 5.9% |
| 净利润同比 | -78.8% | 3.9% |
| 每股收益（稀释后） | $0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DORMRVTY
| Q4 25 | $537.9M | $772.1M | ||
| Q3 25 | $543.7M | $698.9M | ||
| Q2 25 | $541.0M | $720.3M | ||
| Q1 25 | $507.7M | $664.8M | ||
| Q4 24 | $533.8M | $729.4M | ||
| Q3 24 | $503.8M | $684.0M | ||
| Q2 24 | $503.0M | $691.7M | ||
| Q1 24 | $468.7M | $649.9M |
净利润DORMRVTY
| Q4 25 | $11.6M | $98.4M | ||
| Q3 25 | $76.4M | $46.7M | ||
| Q2 25 | $58.7M | $53.9M | ||
| Q1 25 | $57.5M | $42.2M | ||
| Q4 24 | $54.5M | $94.6M | ||
| Q3 24 | $55.3M | $94.4M | ||
| Q2 24 | $47.4M | $55.4M | ||
| Q1 24 | $32.8M | $26.0M |
毛利率DORMRVTY
| Q4 25 | 42.6% | — | ||
| Q3 25 | 44.4% | 53.6% | ||
| Q2 25 | 40.6% | 54.5% | ||
| Q1 25 | 40.9% | 56.5% | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 40.5% | 56.3% | ||
| Q2 24 | 39.6% | 55.7% | ||
| Q1 24 | 38.7% | 54.6% |
营业利润率DORMRVTY
| Q4 25 | 5.8% | 14.5% | ||
| Q3 25 | 19.4% | 11.7% | ||
| Q2 25 | 15.2% | 12.6% | ||
| Q1 25 | 15.8% | 10.9% | ||
| Q4 24 | 16.3% | 16.3% | ||
| Q3 24 | 15.7% | 14.3% | ||
| Q2 24 | 14.4% | 12.4% | ||
| Q1 24 | 11.6% | 6.8% |
净利率DORMRVTY
| Q4 25 | 2.1% | 12.7% | ||
| Q3 25 | 14.1% | 6.7% | ||
| Q2 25 | 10.9% | 7.5% | ||
| Q1 25 | 11.3% | 6.4% | ||
| Q4 24 | 10.2% | 13.0% | ||
| Q3 24 | 11.0% | 13.8% | ||
| Q2 24 | 9.4% | 8.0% | ||
| Q1 24 | 7.0% | 4.0% |
每股收益（稀释后）DORMRVTY
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $2.48 | $0.40 | ||
| Q2 25 | $1.91 | $0.46 | ||
| Q1 25 | $1.87 | $0.35 | ||
| Q4 24 | $1.76 | $0.77 | ||
| Q3 24 | $1.80 | $0.77 | ||
| Q2 24 | $1.53 | $0.45 | ||
| Q1 24 | $1.05 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.4M | $919.9M |
| 总债务越低越好 | $440.6M | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $2.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资DORMRVTY
| Q4 25 | $49.4M | $919.9M | ||
| Q3 25 | $55.5M | $931.4M | ||
| Q2 25 | $56.8M | $991.8M | ||
| Q1 25 | $60.6M | $1.1B | ||
| Q4 24 | $57.1M | $1.2B | ||
| Q3 24 | $45.1M | $1.2B | ||
| Q2 24 | $47.5M | $2.0B | ||
| Q1 24 | $34.4M | $1.7B |
总债务DORMRVTY
| Q4 25 | $440.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $468.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DORMRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产DORMRVTY
| Q4 25 | $2.5B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.3B | $13.4B | ||
| Q1 24 | $2.2B | $13.4B |
负债/权益比DORMRVTY
| Q4 25 | 0.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $41.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $33.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.2% | 21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $75.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DORMRVTY
| Q4 25 | $41.6M | $182.0M | ||
| Q3 25 | $12.2M | $138.5M | ||
| Q2 25 | $8.5M | $134.3M | ||
| Q1 25 | $51.2M | $128.2M | ||
| Q4 24 | $71.4M | $174.2M | ||
| Q3 24 | $44.3M | $147.9M | ||
| Q2 24 | $63.3M | $158.6M | ||
| Q1 24 | $52.0M | $147.6M |
自由现金流DORMRVTY
| Q4 25 | $33.5M | $161.8M | ||
| Q3 25 | $1.8M | $120.0M | ||
| Q2 25 | $98.0K | $115.5M | ||
| Q1 25 | $40.3M | $112.2M | ||
| Q4 24 | $63.2M | $149.8M | ||
| Q3 24 | $35.7M | $125.6M | ||
| Q2 24 | $51.4M | $136.6M | ||
| Q1 24 | $41.2M | $129.7M |
自由现金流率DORMRVTY
| Q4 25 | 6.2% | 21.0% | ||
| Q3 25 | 0.3% | 17.2% | ||
| Q2 25 | 0.0% | 16.0% | ||
| Q1 25 | 7.9% | 16.9% | ||
| Q4 24 | 11.8% | 20.5% | ||
| Q3 24 | 7.1% | 18.4% | ||
| Q2 24 | 10.2% | 19.7% | ||
| Q1 24 | 8.8% | 20.0% |
资本支出强度DORMRVTY
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 2.3% | 2.7% |
现金转化率DORMRVTY
| Q4 25 | 3.60× | 1.85× | ||
| Q3 25 | 0.16× | 2.97× | ||
| Q2 25 | 0.15× | 2.49× | ||
| Q1 25 | 0.89× | 3.03× | ||
| Q4 24 | 1.31× | 1.84× | ||
| Q3 24 | 0.80× | 1.57× | ||
| Q2 24 | 1.34× | 2.87× | ||
| Q1 24 | 1.58× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DORM
| Light Duty | $428.6M | 80% |
| Heavy Duty | $55.8M | 10% |
| Specialty Vehicle | $53.5M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
